Moreover, human melanomas with attenuated IFN-γ signaling or ICB resistance exhibit reduced expression of T cell signature genes and alteration of target genes downstream of mTOR and JAK1/2 pathways, suggestive of their activation. The gene discussed is JAK1; the disease is melanoma.